Jing Xue

List of Publications by Year in descending order

32 papers	2,492 citations	516561 16 h-index	454834 30 g-index
34 all docs	34 docs citations	34 times ranked	5964 citing authors

#	Article	IF	Citations
1	The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature, 2020, 583, 830-833.	13.7	992
2	Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science, 2020, 369, 818-823.	6.0	416
3	Ageâ€related rhesus macaque models of COVIDâ€19. Animal Models and Experimental Medicine, 2020, 3, 93-97.	1.3	238
4	Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques. Nature Communications, 2020, 11, 4400.	5.8	161
5	SARS-CoV-2 crosses the bloodâ€“brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduction and Targeted Therapy, 2021, 6, 337.	7.1	157
6	Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 via Close Contact and Respiratory Droplets Among Human Angiotensin-Converting Enzyme 2 Mice. Journal of Infectious Diseases, 2020, 222, 551-555.	1.9	61
7	A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly PotentIn Vitro,Ex Vivo, andIn VivoAntiviral Activity. Journal of Virology, 2017, 91, .	1.5	53
8	SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters. Frontiers in Microbiology, 2020, 11, 618891.	1.5	46
9	Susceptibility and Attenuated Transmissibility of SARS-CoV-2 in Domestic Cats. Journal of Infectious Diseases, 2021, 223, 1313-1321.	1.9	46
10	Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza. Signal Transduction and Targeted Therapy, 2021, 6, 200.	7.1	41
11	Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo. Signal Transduction and Targeted Therapy, 2020, 5, 66.	7.1	38
12	Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques. PLoS Pathogens, 2019, 15, e1007552.	2.1	30
13	Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models. Journal of Virology, 2018, 92, .	1.5	29
14	Deglycosylation of FcÎ±R at N58 increases its binding to IgA. Glycobiology, 2010, 20, 905-915.	1.3	28
15	Lactobacillus rhamnosusGG attenuates tenofovir disoproxil fumarate-induced bone loss in male miceviagut-microbiota-dependent anti-inflammation. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231986065.	1.1	27
16	Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 2022, 185, 131-144.e18.	13.5	24
17	CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques. Nature Communications, 2019, 10, 2257.	5.8	18
18	SARSâ€CoVâ€2 infection aggravates chronic comorbidities of cardiovascular diseases and diabetes in mice. Animal Models and Experimental Medicine, 2021, 4, 2-15.	1.3	17

#	Article	IF	Citations
19	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008082.	2.1	16
20	Probiotics protect against tenofovirâ€induced mandibular bone loss in mice by rescuing mandibleâ€derived mesenchymal stem cell proliferation and osteogenic differentiation. Journal of Oral Rehabilitation, 2020, 47, 83-90.	1.3	11
21	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Science Translational Medicine, 2020, 12, .	5.8	10
22	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2019, 93, .	1.5	8
23	Efficient Transduction of Human and Rhesus Macaque Primary T Cells by a Modified Human Immunodeficiency Virus Type 1â€"Based Lentiviral Vector. Human Gene Therapy, 2017, 28, 271-285.	1.4	7
24	Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection. Viruses, 2022, 14, 581.	1.5	7
25	Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	3
26	The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice. Journal of Cardiovascular Translational Research, 2022, 15, 38-48.	1.1	3
27	Stage-Dependent Within-Individual Comparison Reveals SIV-Specific Activation/Exhaustion Shift in Rhesus Macaques. Frontiers in Microbiology, 2021, 12, 704449.	1.5	2
28	Does Mucosal B1 Activation Result in the Accumulation of Peak IgM During Chronic Intrarectal SIVmac239 Exposure to Protect Chinese-Origin Rhesus Macaques From Disease Progression?. Frontiers in Microbiology, 2020, 11, 357.	1.5	1
29	Construction of a comprehensive observer-based scale assessing aging-related health and functioning in captive rhesus macaques. Aging, 2019, 11, 6892-6903.	1.4	1
30	Therapeutic effect of (5R)-5-hydroxytriptolide (LLDT-8) in SIV infected rhesus monkeys. International Immunopharmacology, 2022, 110, 108932.	1.7	1
31	A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile. Pharmaceuticals, 2022, 15, 424.	1.7	0
32	Protocol for evaluating CD8+ TÂcell-mediated immunity in latently SHIV-infected rhesus macaques with HIV fusion-inhibitory lipopeptide monotherapy. STAR Protocols, 2022, 3, 101479.	0.5	0